Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Esketamine (January) | 2020

View Archived Issues

CME Post-Test - Esketamine, TCPR, January 2020

January 13, 2020

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

How to Treat Tardive Dyskinesia

January 13, 2020

Chris Aiken, MD.

The VMAT2 inhibitors are FDA approved for tardive dyskinesia (TD), but there are 8 off-label options to consider as well. See how they stack up here, and learn why the atypical antipsychotics ─ with one exception ─ have not put an end to this insidious side effect. Read More

Getting Uncomfortable with Esketamine

January 13, 2020

Nolan Williams, MD

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University. Read More

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020

Chris Aiken, MD.

Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials. Read More

TMS: Deeper is not Better

January 13, 2020

Edmund S. Higgins, MD.

Two devices are available for transcranial magnetic stimulation (TMS). Neurostar came first with the figure-8 coil, which is now off-patent, while Brainsway’s H-coil which claims to reach deeper into the cerebral cortex. See how they compare in the first head-to-head controlled trial, undertaken without industry support. Read More

In Brief: Antipsychotic Update

January 13, 2020

FDA Clears the Path for Magic Mushrooms. Psilocybin, the psychedelic compound in magic mushrooms, was fast-tracked by the FDA for major depression in November 2019. Read More